Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection

三阴性乳腺癌 乳腺癌 化疗 医学 肿瘤科 新辅助治疗 癌症 内科学 癌症研究 病理
作者
Brian D. Lehmann,Bojana Jovanović,Xi Chen,Mónica V. Estrada,Kimberly N. Johnson,Yu Shyr,Harold L. Moses,Melinda E. Sanders,Jennifer A. Pietenpol
出处
期刊:PLOS ONE [Public Library of Science]
卷期号:11 (6): e0157368-e0157368 被引量:1289
标识
DOI:10.1371/journal.pone.0157368
摘要

Triple-negative breast cancer (TNBC) is a heterogeneous disease that can be classified into distinct molecular subtypes by gene expression profiling. Considered a difficult-to-treat cancer, a fraction of TNBC patients benefit significantly from neoadjuvant chemotherapy and have far better overall survival. Outside of BRCA1/2 mutation status, biomarkers do not exist to identify patients most likely to respond to current chemotherapy; and, to date, no FDA-approved targeted therapies are available for TNBC patients. Previously, we developed an approach to identify six molecular subtypes TNBC (TNBCtype), with each subtype displaying unique ontologies and differential response to standard-of-care chemotherapy. Given the complexity of the varying histological landscape of tumor specimens, we used histopathological quantification and laser-capture microdissection to determine that transcripts in the previously described immunomodulatory (IM) and mesenchymal stem-like (MSL) subtypes were contributed from infiltrating lymphocytes and tumor-associated stromal cells, respectively. Therefore, we refined TNBC molecular subtypes from six (TNBCtype) into four (TNBCtype-4) tumor-specific subtypes (BL1, BL2, M and LAR) and demonstrate differences in diagnosis age, grade, local and distant disease progression and histopathology. Using five publicly available, neoadjuvant chemotherapy breast cancer gene expression datasets, we retrospectively evaluated chemotherapy response of over 300 TNBC patients from pretreatment biopsies subtyped using either the intrinsic (PAM50) or TNBCtype approaches. Combined analysis of TNBC patients demonstrated that TNBC subtypes significantly differ in response to similar neoadjuvant chemotherapy with 41% of BL1 patients achieving a pathological complete response compared to 18% for BL2 and 29% for LAR with 95% confidence intervals (CIs; [33, 51], [9, 28], [17, 41], respectively). Collectively, we provide pre-clinical data that could inform clinical trials designed to test the hypothesis that improved outcomes can be achieved for TNBC patients, if selection and combination of existing chemotherapies is directed by knowledge of molecular TNBC subtypes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
DW发布了新的文献求助10
刚刚
DW发布了新的文献求助10
刚刚
1秒前
乐乐的应助被今天没有哭鸭采纳,获得10
1秒前
DW发布了新的文献求助10
1秒前
瘦瘦寻菡发布了新的文献求助10
1秒前
1秒前
bomv发布了新的文献求助10
2秒前
Potato发布了新的文献求助30
2秒前
2秒前
2秒前
2秒前
3秒前
hml123发布了新的文献求助10
3秒前
DW发布了新的文献求助30
4秒前
DW发布了新的文献求助10
4秒前
DW发布了新的文献求助10
4秒前
DW发布了新的文献求助10
4秒前
4秒前
CodeCraft的应助被cz采纳,获得10
4秒前
4秒前
4秒前
FashionBoy的应助被桃桃采纳,获得10
4秒前
4秒前
DW发布了新的文献求助10
4秒前
5秒前
艾格的应助被身处人海采纳,获得10
5秒前
5秒前
6秒前
6秒前
bml发布了新的文献求助10
6秒前
6秒前
7秒前
DW发布了新的文献求助10
7秒前
静默发布了新的文献求助10
7秒前
DW发布了新的文献求助10
7秒前
8秒前
完美世界的应助被Jerry采纳,获得10
8秒前
Lucas的应助被谨慎的南露采纳,获得10
9秒前
11发布了新的文献求助10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188221
求助须知:如何正确求助?哪些是违规求助? 9576025
关于积分的说明 21845049
捐赠科研通 7786165
什么是DOI,文献DOI怎么找? 3435226
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482157